{
  "id": "601cb2e41cb411341a000023",
  "type": "factoid",
  "question": "Dasatinib and Blinatumomab are used for treatment of which disease?",
  "ideal_answer": "Dasatinib and Blinatumomab produces molecular responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33168588",
    "http://www.ncbi.nlm.nih.gov/pubmed/32569380",
    "http://www.ncbi.nlm.nih.gov/pubmed/20038231",
    "http://www.ncbi.nlm.nih.gov/pubmed/33085860",
    "http://www.ncbi.nlm.nih.gov/pubmed/32170867"
  ],
  "snippets": [
    {
      "text": "Tyrosine kinase inhibitors (imatinib or dasatinib) were added in Philadelphia chromosome-positive (Ph-positive) ALL. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32170867",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, combined BCL-2 or MCL1 inhibition with dasatinib showed potent killing in primary Ph+ B-ALL cases, but the BH3-mimetic combination appeared superior in vitro in a variety of Ph-like ALL samples. In PDX models, combined BCL-2 and MCL1 targeting eradicated ALL from Ph- and Ph+ B-ALL cases, although fatal tumor lysis was observed in some instances of high tumor burden. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32569380",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase II trial shows that a chemotherapy-free regimen of dasatinib and blinatumomab produces molecular responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33168588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33085860",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: We conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33085860",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: A chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33085860",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase II trial shows that a chemotherapy-free regimen of dasatinib and blinatumomab produces molecular responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33168588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: A chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Fun",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33085860",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dasatinib is a dual BCR-ABL/Src-family kinase (SFK) inhibitor approved for patients with imatinib-resistant and -intolerant CML in any phase and Ph+ ALL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20038231",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Philadelphia chromosome-positive acute lymphoblastic leukemia"
}